Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. I...
Gespeichert in:
| Veröffentlicht in: | Kidney diseases 2020-05, Vol.6 (3), p.144-149 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 3 |
| container_start_page | 144 |
| container_title | Kidney diseases |
| container_volume | 6 |
| creator | Mei, Chang-Lin Xue, Cheng Yu, Sheng-Qiang Dai, Bing Chen, Jiang-Hua Li, Ying Chen, Li-Meng Liu, Zhang-Suo Wu, Yong-Gui Hu, Zhao Zha, Yan Liu, Hong Zhuang, Yong-Ze Zhang, Chun Xiao, Xiang-Cheng Wang, Yue Li, Gui-Sen Ma, Yi-Yi Li, Lin |
| description | Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary. |
| doi_str_mv | 10.1159/000506288 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A726965648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A726965648</galeid><doaj_id>oai_doaj_org_article_99fa78c52e7b4bb78d763a58b5b0a32d</doaj_id><sourcerecordid>A726965648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-ade250df75b1617f8770a4dc529502b2e6ea5c2fcf120404c1dd4edf46d92dfb3</originalsourceid><addsrcrecordid>eNptklFrFDEQgBdRbKl98F0k4Is-XE2ym2TXB-G41losWFCfQzaZ3KXuJm2yW7x_b657XTyQPEyY-eZjBqYoXhN8RghrPmKMGea0rp8Vx5Q2fNGUTDyf_zU5Kk5Tus0YYQQLwl8WRyVltGwYPy42F39Aj4N7APRj7HsVt5_QqnPeadWhm6j04DSgy9EZyFlANkS0HIeQQp-B89A7r_yAbkK31duUYfTNGQ9bdO4SqATIebTaZOhV8cKqLsHpPp4Uv75c_Fx9XVx_v7xaLa8XmtFmWCgDlGFjBWsJJ8LWQmBVmV2RYdpS4KCYplZbQnGFK02MqcDYipuGGtuWJ8XV5DVB3cq76HY7yaCcfEyEuJYq5jk7kE1jlaizGkRbta2ojeClYnXLWqxKarLr8-S6G9sejAY_RNUdSA8r3m3kOjxIQTkTuMyC93tBDPcjpEH2LmnoOuUhjEnSilBKakxERt9N6Frl0Zy3IRv1DpfLrGs441WdqbP_UPkZ6J0OHqzL-YOGD1ODjiGlCHaenmC5ux85309m3_677kw-XUsG3kzAbxXXEGdg3_8X1XPJAQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2412218017</pqid></control><display><type>article</type><title>Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China</title><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mei, Chang-Lin ; Xue, Cheng ; Yu, Sheng-Qiang ; Dai, Bing ; Chen, Jiang-Hua ; Li, Ying ; Chen, Li-Meng ; Liu, Zhang-Suo ; Wu, Yong-Gui ; Hu, Zhao ; Zha, Yan ; Liu, Hong ; Zhuang, Yong-Ze ; Zhang, Chun ; Xiao, Xiang-Cheng ; Wang, Yue ; Li, Gui-Sen ; Ma, Yi-Yi ; Li, Lin</creator><creatorcontrib>Mei, Chang-Lin ; Xue, Cheng ; Yu, Sheng-Qiang ; Dai, Bing ; Chen, Jiang-Hua ; Li, Ying ; Chen, Li-Meng ; Liu, Zhang-Suo ; Wu, Yong-Gui ; Hu, Zhao ; Zha, Yan ; Liu, Hong ; Zhuang, Yong-Ze ; Zhang, Chun ; Xiao, Xiang-Cheng ; Wang, Yue ; Li, Gui-Sen ; Ma, Yi-Yi ; Li, Lin ; ADPKD Clinical Guideline Working Group</creatorcontrib><description>Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.</description><identifier>ISSN: 2296-9381</identifier><identifier>EISSN: 2296-9357</identifier><identifier>DOI: 10.1159/000506288</identifier><identifier>PMID: 32523956</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>autosomal dominant polycystic kidney disease ; Care and treatment ; Chronic kidney failure ; diagnosis ; end-stage renal disease ; gene ; Guidelines ; Medical research ; Medicine, Experimental ; Polycystic kidney disease ; treatment</subject><ispartof>Kidney diseases, 2020-05, Vol.6 (3), p.144-149</ispartof><rights>2020 The Author(s) Published by S. Karger AG, Basel</rights><rights>Copyright © 2020 by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2020 S. Karger AG</rights><rights>Copyright © 2020 by S. Karger AG, Basel 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-ade250df75b1617f8770a4dc529502b2e6ea5c2fcf120404c1dd4edf46d92dfb3</citedby><orcidid>0000-0003-3565-8024 ; 0000-0003-1970-9979 ; 0000-0002-4132-9406</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265703/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265703/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27635,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32523956$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mei, Chang-Lin</creatorcontrib><creatorcontrib>Xue, Cheng</creatorcontrib><creatorcontrib>Yu, Sheng-Qiang</creatorcontrib><creatorcontrib>Dai, Bing</creatorcontrib><creatorcontrib>Chen, Jiang-Hua</creatorcontrib><creatorcontrib>Li, Ying</creatorcontrib><creatorcontrib>Chen, Li-Meng</creatorcontrib><creatorcontrib>Liu, Zhang-Suo</creatorcontrib><creatorcontrib>Wu, Yong-Gui</creatorcontrib><creatorcontrib>Hu, Zhao</creatorcontrib><creatorcontrib>Zha, Yan</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Zhuang, Yong-Ze</creatorcontrib><creatorcontrib>Zhang, Chun</creatorcontrib><creatorcontrib>Xiao, Xiang-Cheng</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Li, Gui-Sen</creatorcontrib><creatorcontrib>Ma, Yi-Yi</creatorcontrib><creatorcontrib>Li, Lin</creatorcontrib><creatorcontrib>ADPKD Clinical Guideline Working Group</creatorcontrib><title>Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China</title><title>Kidney diseases</title><addtitle>Kidney Dis</addtitle><description>Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.</description><subject>autosomal dominant polycystic kidney disease</subject><subject>Care and treatment</subject><subject>Chronic kidney failure</subject><subject>diagnosis</subject><subject>end-stage renal disease</subject><subject>gene</subject><subject>Guidelines</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Polycystic kidney disease</subject><subject>treatment</subject><issn>2296-9381</issn><issn>2296-9357</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptklFrFDEQgBdRbKl98F0k4Is-XE2ym2TXB-G41losWFCfQzaZ3KXuJm2yW7x_b657XTyQPEyY-eZjBqYoXhN8RghrPmKMGea0rp8Vx5Q2fNGUTDyf_zU5Kk5Tus0YYQQLwl8WRyVltGwYPy42F39Aj4N7APRj7HsVt5_QqnPeadWhm6j04DSgy9EZyFlANkS0HIeQQp-B89A7r_yAbkK31duUYfTNGQ9bdO4SqATIebTaZOhV8cKqLsHpPp4Uv75c_Fx9XVx_v7xaLa8XmtFmWCgDlGFjBWsJJ8LWQmBVmV2RYdpS4KCYplZbQnGFK02MqcDYipuGGtuWJ8XV5DVB3cq76HY7yaCcfEyEuJYq5jk7kE1jlaizGkRbta2ojeClYnXLWqxKarLr8-S6G9sejAY_RNUdSA8r3m3kOjxIQTkTuMyC93tBDPcjpEH2LmnoOuUhjEnSilBKakxERt9N6Frl0Zy3IRv1DpfLrGs441WdqbP_UPkZ6J0OHqzL-YOGD1ODjiGlCHaenmC5ux85309m3_677kw-XUsG3kzAbxXXEGdg3_8X1XPJAQ</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Mei, Chang-Lin</creator><creator>Xue, Cheng</creator><creator>Yu, Sheng-Qiang</creator><creator>Dai, Bing</creator><creator>Chen, Jiang-Hua</creator><creator>Li, Ying</creator><creator>Chen, Li-Meng</creator><creator>Liu, Zhang-Suo</creator><creator>Wu, Yong-Gui</creator><creator>Hu, Zhao</creator><creator>Zha, Yan</creator><creator>Liu, Hong</creator><creator>Zhuang, Yong-Ze</creator><creator>Zhang, Chun</creator><creator>Xiao, Xiang-Cheng</creator><creator>Wang, Yue</creator><creator>Li, Gui-Sen</creator><creator>Ma, Yi-Yi</creator><creator>Li, Lin</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3565-8024</orcidid><orcidid>https://orcid.org/0000-0003-1970-9979</orcidid><orcidid>https://orcid.org/0000-0002-4132-9406</orcidid></search><sort><creationdate>20200501</creationdate><title>Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China</title><author>Mei, Chang-Lin ; Xue, Cheng ; Yu, Sheng-Qiang ; Dai, Bing ; Chen, Jiang-Hua ; Li, Ying ; Chen, Li-Meng ; Liu, Zhang-Suo ; Wu, Yong-Gui ; Hu, Zhao ; Zha, Yan ; Liu, Hong ; Zhuang, Yong-Ze ; Zhang, Chun ; Xiao, Xiang-Cheng ; Wang, Yue ; Li, Gui-Sen ; Ma, Yi-Yi ; Li, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-ade250df75b1617f8770a4dc529502b2e6ea5c2fcf120404c1dd4edf46d92dfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>autosomal dominant polycystic kidney disease</topic><topic>Care and treatment</topic><topic>Chronic kidney failure</topic><topic>diagnosis</topic><topic>end-stage renal disease</topic><topic>gene</topic><topic>Guidelines</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Polycystic kidney disease</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mei, Chang-Lin</creatorcontrib><creatorcontrib>Xue, Cheng</creatorcontrib><creatorcontrib>Yu, Sheng-Qiang</creatorcontrib><creatorcontrib>Dai, Bing</creatorcontrib><creatorcontrib>Chen, Jiang-Hua</creatorcontrib><creatorcontrib>Li, Ying</creatorcontrib><creatorcontrib>Chen, Li-Meng</creatorcontrib><creatorcontrib>Liu, Zhang-Suo</creatorcontrib><creatorcontrib>Wu, Yong-Gui</creatorcontrib><creatorcontrib>Hu, Zhao</creatorcontrib><creatorcontrib>Zha, Yan</creatorcontrib><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Zhuang, Yong-Ze</creatorcontrib><creatorcontrib>Zhang, Chun</creatorcontrib><creatorcontrib>Xiao, Xiang-Cheng</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Li, Gui-Sen</creatorcontrib><creatorcontrib>Ma, Yi-Yi</creatorcontrib><creatorcontrib>Li, Lin</creatorcontrib><creatorcontrib>ADPKD Clinical Guideline Working Group</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mei, Chang-Lin</au><au>Xue, Cheng</au><au>Yu, Sheng-Qiang</au><au>Dai, Bing</au><au>Chen, Jiang-Hua</au><au>Li, Ying</au><au>Chen, Li-Meng</au><au>Liu, Zhang-Suo</au><au>Wu, Yong-Gui</au><au>Hu, Zhao</au><au>Zha, Yan</au><au>Liu, Hong</au><au>Zhuang, Yong-Ze</au><au>Zhang, Chun</au><au>Xiao, Xiang-Cheng</au><au>Wang, Yue</au><au>Li, Gui-Sen</au><au>Ma, Yi-Yi</au><au>Li, Lin</au><aucorp>ADPKD Clinical Guideline Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China</atitle><jtitle>Kidney diseases</jtitle><addtitle>Kidney Dis</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>6</volume><issue>3</issue><spage>144</spage><epage>149</epage><pages>144-149</pages><issn>2296-9381</issn><eissn>2296-9357</eissn><abstract>Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>32523956</pmid><doi>10.1159/000506288</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3565-8024</orcidid><orcidid>https://orcid.org/0000-0003-1970-9979</orcidid><orcidid>https://orcid.org/0000-0002-4132-9406</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2296-9381 |
| ispartof | Kidney diseases, 2020-05, Vol.6 (3), p.144-149 |
| issn | 2296-9381 2296-9357 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A726965648 |
| source | DOAJ Directory of Open Access Journals; Karger Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | autosomal dominant polycystic kidney disease Care and treatment Chronic kidney failure diagnosis end-stage renal disease gene Guidelines Medical research Medicine, Experimental Polycystic kidney disease treatment |
| title | Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T04%3A18%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Executive%20Summary:%20Clinical%20Practice%20Guideline%20for%20Autosomal%20Dominant%20Polycystic%20Kidney%20Disease%20in%20China&rft.jtitle=Kidney%20diseases&rft.au=Mei,%20Chang-Lin&rft.aucorp=ADPKD%C2%A0Clinical%C2%A0Guideline%C2%A0Working%C2%A0Group&rft.date=2020-05-01&rft.volume=6&rft.issue=3&rft.spage=144&rft.epage=149&rft.pages=144-149&rft.issn=2296-9381&rft.eissn=2296-9357&rft_id=info:doi/10.1159/000506288&rft_dat=%3Cgale_cross%3EA726965648%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2412218017&rft_id=info:pmid/32523956&rft_galeid=A726965648&rft_doaj_id=oai_doaj_org_article_99fa78c52e7b4bb78d763a58b5b0a32d&rfr_iscdi=true |